Wolber, Philipp, Nachtsheim, Lisa, Hoffmann, Franziska ORCID: 0000-0002-6872-924X, Klussmann, Jens Peter ORCID: 0000-0002-8223-7954, Meyer, Moritz, von Eggeling, Ferdinand ORCID: 0000-0002-8062-6999, Guntinas-Lichius, Orlando ORCID: 0000-0001-9671-0784, Quaas, Alexander and Arolt, Christoph (2021). Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target. Head Neck Pathol., 15 (4). S. 1147 - 1156. NEW YORK: SPRINGER. ISSN 1936-0568

Full text not available from this repository.


Treatment options for unresectable, recurrent or metastatic salivary gland carcinomas (SGC) are scarce. Trophoblast cell surface antigen 2 (Trop-2) is a transmembrane glycoprotein that is involved in a variety of oncogenic cell signaling pathways. Its potential as a target for the antibody-drug conjugate sacituzumab govitecan has already been demonstrated in different tumor entities. The United States Food and Drug Administration approved this antibody-drug conjugate for the treatment of metastatic triple-negative breast cancer. Here, we aimed to investigate Trop-2 protein expression in different entities of SGCs. We retrospectively reviewed the medical records of all patients that underwent surgery for a primary SGC in a tertiary referral center between 1990 and 2014. Immunohistochemical (IHC) staining for Trop-2 was performed and rated as negative, weak, moderate or high using a semiquantitative score. Additionally, representative cases were analyzed using MALDI-mass spectrometry (MS) imaging to confirm the IHC results. The cohort consisted of 114 tumors of the parotid gland (90.4%) and submandibular gland (9.6%). It mainly included mucoepidermoid, salivary duct and adenoid cystic carcinomas. In IHC samples, 44% showed high, 38% moderate and 10% weak expression rates of Trop-2. MALDI-MS imaging confirmed the presence of Trop-2 protein in 80% of the tested tumor samples. This is the first study to demonstrate that several types of SGC express Trop-2 with variable intensity. Since there are currently few systemic treatment options for advanced SGCs, Trop-2 represents a promising target for further clinical studies, for instance, with sacituzumab govitecan.

Item Type: Journal Article
CreatorsEmailORCIDORCID Put Code
Hoffmann, FranziskaUNSPECIFIEDorcid.org/0000-0002-6872-924XUNSPECIFIED
Klussmann, Jens PeterUNSPECIFIEDorcid.org/0000-0002-8223-7954UNSPECIFIED
von Eggeling, FerdinandUNSPECIFIEDorcid.org/0000-0002-8062-6999UNSPECIFIED
Guntinas-Lichius, OrlandoUNSPECIFIEDorcid.org/0000-0001-9671-0784UNSPECIFIED
URN: urn:nbn:de:hbz:38-583439
DOI: 10.1007/s12105-021-01325-5
Journal or Publication Title: Head Neck Pathol.
Volume: 15
Number: 4
Page Range: S. 1147 - 1156
Date: 2021
Publisher: SPRINGER
Place of Publication: NEW YORK
ISSN: 1936-0568
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
PathologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/58343


Downloads per month over past year



Actions (login required)

View Item View Item